GABAergic circuits in the basal ganglia and movement disorders

Progress in Brain Research

Volumn 160, Issue , 2007, Pages 287-312

  Galvan, Adriana ^a   Wichmann, Thomas ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

GABA receptors; GABAergic neurons; Hemiballism; Huntington's disease; Parkinson's disease

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; BACLOFEN; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BUDIPINE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUMAZENIL; GABAPENTIN; ISTRADEFYLLINE; LEVODOPA; MUSCIMOL; NEUROLEPTIC AGENT; PROGABIDE; TOPIRAMATE; VALPROIC ACID;

BASAL GANGLION; BRAIN DEPTH STIMULATION; BRAIN NERVE CELL; DRUG POTENTIATION; DYSKINESIA; DYSTONIA; ELECTROPHYSIOLOGY; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; HEMIBALLISM; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; NERVOUS SYSTEM FUNCTION; NEUROANATOMY; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANIMALS; BASAL GANGLIA; GABA MODULATORS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MOVEMENT DISORDERS; NEURAL INHIBITION; NEURAL PATHWAYS; RECEPTORS, GABA; SYNAPTIC TRANSMISSION;

EID: 34247866195     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(06)60017-4     Document Type: Review

References (270)

1. Albin R.L., Young A.B., and Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12 (1989) 366-375
2. Albright A.L., Barry M.J., Fasick P., Barron W., and Shultz B. Continuous intrathecal baclofen infusion for symptomatic generalized dystonia. Neurosurgery 38 (1996) 934-938 (discussion 938-939)
3. Awaad Y., Munoz S., and Nigro M. Progressive dystonia in a child with chromosome 18p deletion, treated with intrathecal baclofen. J. Child Neurol. 14 (1999) 75-77
4. Aziz T.Z., Peggs D., Sambrook M.A., and Crossman A.R. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov. Disord. 6 (1991) 288-292
5. Bachoud-Levi A., Bourdet C., Brugieres P., Nguyen J.P., Grandmougin T., Haddad B., Jeny R., Bartolomeo P., Boisse M.F., Barba G.D., Degos J.D., Ergis A.M., Lefaucheur J.P., Lisovoski F., Pailhous E., Remy P., Palfi S., Defer G.L., Cesaro P., Hantraye P., and Peschanski M. Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp. Neurol. 161 (2000) 194-202
6. Bachoud-Levi A.C., Remy P., Nguyen J.P., Brugieres P., Lefaucheur J.P., Bourdet C., Baudic S., Gaura V., Maison P., Haddad B., Boisse M.F., Grandmougin T., Jeny R., Bartolomeo P., Dalla Barba G., Degos J.D., Lisovoski F., Ergis A.M., Pailhous E., Cesaro P., Hantraye P., and Peschanski M. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 356 (2000) 1975-1979
7. Bahena-Trujillo R., and Arias-Montano J.A. [3H] gamma-aminobutyric acid transport in rat substantia nigra pars reticulata synaptosomes: pharmacological characterization and phorbol ester-induced inhibition. Neurosci. Lett. 274 (1999) 119-122
8. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., and Chase T.N. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.[see comment]. Neurology 61 (2003) 293-396
9. i pallidotomy: 1 year pilot-study results. Ann. Neurol. 40 (1996) 355-366
10. Baron M.S., Wichmann T., Ma D., and DeLong M.R. Effects of transient focal inactivation of the basal ganglia in parkinsonian primates. J. Neurosci. 22 (2002) 299-592
11. Bauer A., Zilles K., Matusch A., Holzmann C., Riess O., and von Horsten S. Regional and subtype selective changes of neurotransmitter receptor density in a rat transgenic for the Huntington's disease mutation. J. Neurochem. 94 (2005) 639-650
12. Baufreton J., Atherton J.F., Surmeier D.J., and Bevan M.D. Enhancement of excitatory synaptic integration by GABAergic inhibition in the subthalamic nucleus. J. Neurosci. 25 (2005) 8505-8517
13. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., and Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13 (1993) 4181-4192
14. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., and Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321 (1986) 168-171
15. Becker R.E., and Lal H. Pharmacological approaches to treatment of hemiballism and hemichorea. Brain Res. Bull. 11 (1983) 187-189
16. Bergman H., Wichmann T., and DeLong M.R. Amelioration of parkinsonian symptoms by inactivation of the subthalamic nucleus (STN) in MPTP treated green monkeys. Mov. Disord. 5 Suppl. 1 (1990) 79
17. Bergman H., Wichmann T., and DeLong M.R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249 (1990) 1436-1438
18. Bergman H., Wichmann T., Karmon B., and DeLong M.R. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol. 72 (1994) 507-520
19. Betarbet R., Turner R., Chockkan V., DeLong M.R., Allers K.A., Walters J., Levey A.I., and Greenamyre J.T. Dopaminergic neurons intrinsic to the primate striatum. J. Neurosci. 17 (1997) 6761-6768
20. Beurrier C., Congar P., Bioulac B., and Hammond C. Subthalamic nucleus neurons switch from single-spike activity to burst-firing mode. J. Neurosci. 19 (1999) 599-609
21. Bevan M.D., Magill P.J., Terman D., Bolam J.P., and Wilson C.J. Move to the rhythm: oscillations in the subthalamic nucleus-external globus pallidus network. Trends Neurosci. 25 (2002) 525-531
22. Bibbiani F., Oh J.D., Petzer J.P., Castagnoli Jr. N., Chen J.F., Schwarzschild M.A., and Chase T.N. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease [see comment]. Exp. Neurol. 184 (2003) 285-294
23. Billings L.M., and Marshall J.F. Glutamic acid decarboxylase 67 mRNA regulation in two globus pallidus neuron populations by dopamine and the subthalamic nucleus. J. Neurosci. 24 (2004) 3094-3103
24. Bonilla E., Prasad A.L., and Arrieta A. Huntington's disease: studies on brain free amino acids. Life Science 42 (1988) 1153-1158
25. Boraud T., Bezard E., Bioulac B., and Gross C.E. Ratio of inhibited-to-activated pallidal neurons decreases dramatically during passive limb movement in the MPTP-treated monkey. J. Neurophysiol. 83 (2000) 1760-1763
26. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003) 197-211
27. Brickell K.L., Nicholson L.F., Waldvogel H.J., and Faull R.L. Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: a detailed time course of the cellular and GABA(A) receptor changes. J. Chem. Neuroanat. 17 (1999) 75-97
28. Brooks D.J. The role of the basal ganglia in motor control: contributions from PET. J. Neurol. Sci. 128 (1995) 1-13
29. Brouillet E., Conde F., Beal M.F., and Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59 (1999) 427-468
30. Brown P. Oscillatory nature of human basal ganglia activity: relationship to the pathophysiology of Parkinson's disease. Mov. Disord. 18 (2003) 357-363
31. Burbaud P., Bonnet B., Guehl D., Lagueny A., and Bioulac B. Movement disorders induced by gamma-aminobutyric agonist and antagonist injections into the internal globus pallidus and substantia nigra pars reticulata of the monkey. Brain Res. 780 (1998) 102-107
32. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., and Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80 (1983) 4546-4550
33. Calon F., and Di Paolo T. Levodopa response motor complications-GABA receptors and preproenkephalin expression in human brain. Parkinsonism Relat. Disord. 8 (2002) 449-454
34. Calon F., Goulet M., Blanchet P.J., Martel J.C., Piercey M.F., Bédard P.J., and Di Paolo T. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex. Brain Res. 680 (1995) 43-52
35. Calon F., Lavertu N., Lemieux A.M., Morissette M., Goulet M., Grondin R., Blanchet P.J., Bedard P.J., and Di Paolo T. Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter. Synapse 40 (2001) 225-234
36. Calon F., Morissette M., Goulet M., Grondin R., Blanchet P.J., Bedard P.J., and Di Paolo T. Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content. Neurochem. Int. 35 (1999) 81-91
37. Calon F., Morissette M., Goulet M., Grondin R., Blanchet P.J., Bedard P.J., and Di Paolo T. 125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments. Exp. Neurol. 163 (2000) 191-199
38. Calon F., Morissette M., Rajput A.H., Hornykiewicz O., Bedard P.J., and Di Paolo T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov. Disord. 18 (2003) 241-253
39. Carlson B.B., Behrstock S., Tobin A.J., and Salamone J.D. Brain implantations of engineered GABA-releasing cells suppress tremor in an animal model of Parkinsonism. Neuroscience 119 (2003) 927-932
40. Carpenter M.B., Whittier J.R., and Mettler F.A. Analysis of choreoid hyperkinesia in the rhesus monkey: surgical and pharmacological analysis of hyperkinesia resulting from lesions in the subthalamic nucleus of Luys. J. Comp. Neurol. 92 (1950) 293-332
41. Carta A., Fenu S., and Morelli M. Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease. Neurol. Sci. 22 (2001) 59-60
42. Casey D.E., Gerlach J., and Christensson E. Dopamine, acetylcholine, and GABA effects in acute dystonia in primates. Psychopharmacology (Berl.) 70 (1980) 83-87
43. Cenci M.A., Lee C.S., and Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10 (1998) 2694-2706
44. Centonze D., Rossi S., Prosperetti C., Tscherter A., Bernardi G., Maccarrone M., and Calabresi P. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biol. Psychiatry 57 (2005) 1583-1589
45. Cepeda C., Starling A.J., Wu N., Nguyen O.K., Uzgil B., Soda T., Andre V.M., Ariano M.A., and Levine M.S. Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. J. Neurosci. Res. 78 (2004) 855-867
46. Chadha A., Dawson L.G., Jenner P.G., and Duty S. Effect of unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway on GABA(A) receptor subunit gene expression in the rodent basal ganglia and thalamus. Neuroscience 95 (2000) 119-126
47. 3H]Ro 15-1788 binding in rat globus pallidus and substantia nigra pars reticulata following a nigrostriatal tract lesion. Brain Res. 862 (2000) 280-283
48. Chandra V., Wharton S., and Spunt A.L. Amelioration of hemiballismus with sodium valproate. Ann. Neurol. 12 (1982) 407
49. Chase T.N., and Oh J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 23 (2000) S86-S91
50. Chen C.C., Lee S.T., Wu T., Chen C.J., Huang C.C., and Lu C.S. Hemiballism after subthalamotomy in patients with Parkinson's disease: report of 2 cases. Mov. Disord. 17 (2002) 1367-1371
51. Chen G.J., Jeng C.H., Lin S.Z., Tsai S.H., Wang Y., and Chiang Y.H. Fetal striatal transplants restore electrophysiological sensitivity to dopamine in the lesioned striatum of rats with experimental Huntington's disease. J. Biomed. Sci. 9 (2002) 303-310
52. Chen L., and Yung W.H. Effects of the GABA-uptake inhibitor tiagabine in rat globus pallidus. Exp. Brain Res. 152 (2003) 263-269
53. Chen R., and Hallett M. Focal dystonia and repetitive motion disorders. Clin. Orthop. Relat. Res. 351 (1998) 102-106
54. Chudnow R.S., Mimbela R.A., Owen D.B., and Roach E.S. Gabapentin for familial paroxysmal dystonic choreoathetosis. Neurology 49 (1997) 1441-1442
55. Cicchetti F., Prensa L., Wu Y., and Parent A. Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res. Brain Res. Rev. 34 (2000) 80-101
56. Cross A.J., and Waddington J.L. Substantia nigra gamma-aminobutyric acid receptors in Huntington's disease. J. Neurochem. 37 (1981) 321-324
57. Crossman A.R., Mitchell I.J., and Sambrook M.A. Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey. Neuropharmacology 24 (1985) 587-591
58. de Groote C., Wullner U., Lochmann P.A., Luiten P.G., and Klockgether T. Functional characterization and expression of thalamic GABA(B) receptors in a rodent model of Parkinson's disease. Neuropharmacology 38 (1999) 1683-1689
59. Delfs J.M., Anegawa N.J., and Chesselet M.F. Glutamate decarboxylase messenger RNA in rat pallidum: comparison of the effects of haloperidol, clozapine and combined haloperidol-scopolamine treatments. Neuroscience 66 (1995) 67-80
60. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13 (1990) 281-285
61. Dinsmore J., Ratliff J., Deacon T., Pakzaban P., Jacoby D., Galpern W., and Isacson O. Embryonic stem cells differentiated in vitro as a novel source of cells for transplantation. Cell Transplant 5 (1996) 131-143
62. Dogali M., Fazzini E., Kolodny E., Eidelberg D., Sterio D., Devinsky O., and Beric A. Stereotactic ventral pallidotomy for Pakinson's disease. Neurology 45 (1995) 753-761
63. Dostrovsky J.O., Hutchison W.D., and Lozano A.M. The globus pallidus, deep brain stimulation, and Parkinson's disease. Neuroscientist 8 (2002) 284-290
64. Driver-Dunckley E., and Evidente V.G. Hemichorea-hemiballismus may respond to topiramate. Clin. Neuropharmacol. 28 (2005) 142-144
65. Dunnett S.B., Carter R.J., Watts C., Torres E.M., Mahal A., Mangiarini L., Bates G., and Morton A.J. Striatal transplantation in a transgenic mouse model of Huntington's disease. Exp. Neurol. 154 (1998) 31-40
66. Dunnett S.B., and Rosser A.E. Cell therapy in Huntington's disease. NeuroRx 1 (2004) 394-405
67. Eidelberg D., Moeller J.R., Ishikawa T., Dhawan V., Spetsieris P., Przedborski S., and Fahn S. The metabolic topography of idiopathic torsion dystonia. Brain 118 (1995) 1473-1484
68. Ellison D.W., Beal M.F., Mazurek M.F., Malloy J.R., Bird E.D., and Martin J.B. Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease. Brain 110 Pt 6 (1987) 1657-1673
69. Fahn S. Systemic therapy of dystonia. Can. J. Neurol. Sci. 14 (1987) 528-532
70. Ferrante R.J., Kowall N.W., Cipolloni P.B., Storey E., and Beal M.F. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Exp. Neurol. 119 (1993) 46-71
71. Filion M., Tremblay L., and Bedard P.J. Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys. Brain Res. 444 (1988) 165-176
72. Ford B., Greene P., Louis E.D., Petzinger G., Bressman S.B., Goodman R., Brin M.F., Sadiq S., and Fahn S. Use of intrathecal baclofen in the treatment of patients with dystonia. Arch. Neurol. 53 (1996) 1241-1246
73. Forno L.S., DeLanney L.E., Irwin I., and Langston J.W. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease. Adv. Neurol. 60 (1993) 600-608
74. Fox S.H., Henry B., Hill M., Crossman A., and Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. 17 (2002) 1180-1187
75. Francois C., Percheron G., Yelnik J., and Heyner S. A Golgi analysis of the primate globus pallidus. I. Inconstant processes of large neurons, other neuronal types, and afferent axons. J. Comp. Neurol. 227 (1984) 182-199
76. Friedman Y., Richter A., Raymond R., Loscher W., and Nobrega J.N. Regional decreases in NK-3, but not NK-1 tachykinin receptor binding in dystonic hamster (dt(sz)) brains. Neuroscience 112 (2002) 639-645
77. Fujiyama F., Stephenson F.A., and Bolam J.P. Synaptic localization of GABA(A) receptor subunits in the substantia nigra of the rat: effects of quinolinic acid lesions of the striatum. Eur. J. Neurosci. 15 (2002) 1961-1975
78. Furtado S., Sossi V., Hauser R.A., Samii A., Schulzer M., Murphy C.B., Freeman T.B., and Stoessl A.J. Positron emission tomography after fetal transplantation in Huntington's disease. Ann. Neurol. 58 (2005) 331-337
79. Galardi G., Perani D., Grassi F., Bressi S., Amadio S., Antoni M., Comi G.C., Canal N., and Fazio F. Basal ganglia and thalamo-cortical hypermetabolism in patients with spasmodic torticollis. Acta Neurol. Scand. 94 (1996) 172-176
80. Galeffi F., Bianchi L., Bolam J.P., and Della Corte L. The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis. Eur. J. Neurosci. 18 (2003) 856-868
81. Galvan A., Villalba R.M., West S.M., Maidment N.T., Ackerson L.C., Smith Y., and Wichmann T. GABAergic modulation of the activity of globus pallidus neurons in primates: in vivo analysis of the functions of GABA receptors and GABA transporters. J. Neurophysiol. 94 (2005) 990-1000
82. Gatev P., Darbin O., and Wichmann T. Oscillations in the basal ganglia under normal conditions and in movement disorders. Mov. Disord. 21 (2006) 1566-1577
83. Gatev P.G., and Wichmann T. Changes in arousal alter neuronal activity in primate basal ganglia. Soc. Neurosci. Abstr. 29 (2003)
84. Gatto E.M., Uribe R.C., Raina G., Gorja M., Folgar S., and Micheli F.E. Vascular hemichorea/hemiballism and topiramate. Mov. Disord. 19 (2004) 836-838
85. Gerlach M., Gsell W., Kornhuber J., Jellinger K., Krieger V., Pantucek F., Vock R., and Riederer P. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain Res. 741 (1996) 142-152
86. Gernert M., Bennay M., Fedrowitz M., Rehders J.H., and Richter A. Altered discharge pattern of basal ganglia output neurons in an animal model of idiopathic dystonia. J. Neurosci. 22 (2002) 7244-7253
87. Gernert M., Richter A., and Loscher W. Alterations in spontaneous single unit activity of striatal subdivisions during ontogenesis in mutant dystonic hamsters. Brain Res. 821 (1999) 277-285
88. Gernert M., Richter A., and Loscher W. In vivo extracellular electrophysiology of pallidal neurons in dystonic and nondystonic hamsters. J. Neurosci. Res. 57 (1999) 894-905
89. Giller C.A., Dewey R.B., Ginsburg M.I., Mendelsohn D.B., and Berk A.M. Stereotactic pallidotomy and thalamotomy using individual variations of anatomic landmarks for localization. Neurosurgery 42 (1998) 56-62
90. Giordano M., Ford L.M., Shipley M.T., and Sanberg P.R. Neural grafts and pharmacological intervention in a model of Huntington's disease. Brain Res. Bull. 25 (1990) 453-465
91. Glass M., Dragunow M., and Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97 (2000) 505-519
92. Gnanalingham K.K., and Robertson R.G. Chronic continuous and intermittent L-3,4-dihydroxyphenylalanine treatments differentially affect basal ganglia function in 6-hydroxydopamine lesioned rats-an autoradiographic study using [3 H]flunitrazepam. Neuroscience 57 (1993) 673-681
93. Graybiel A.M. Building action repertoires: memory and learning functions of the basal ganglia. Curr. Op. Neurobiol. 5 (1995) 733-741
94. Griffiths P.D., Sambrook M.A., Perry R., and Crossman A.R. Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease. J. Neurol. Sci. 100 (1990) 131-136
95. Grofova I., Deniau J.M., and Kitai S.T. Morphology of the substantia nigra pars reticulata projection neurons intracellularly labelled with HRP. J. Comp. Neurol. 208 (1982) 352-368
96. Group H.s.D.C.R. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
97. Guehl D., Burbaud P., Boraud T., and Bioulac B. Bicuculline injections into the rostral and caudal motor thalamus of the monkey induce different types of dystonia. Eur. J. Neurosci. 12 (2000) 1033-1037
98. Guimaraes J., and Vale Santos J. Paroxysmal dystonia induced by exercise and acetazolamide. Eur. J. Neurol. 7 (2000) 237-240
99. Guridi J., Herrero M.T., Luquin M.R., Guillen J., Ruberg M., Laguna J., Vila M., Javoy-Agid F., Agid Y., Hirsch E., and Obeso J.A. Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. Brain 119 (1996) 1717-1727
100. Guridi J., and Obeso J.A. The subthalamic nucleus, hemiballismus and Parkinson's disease: reappraisal of a neurosurgical dogma. Brain 124 (2001) 5-19
101. Hallworth N.E., and Bevan M.D. Globus pallidus neurons dynamically regulate the activity pattern of subthalamic nucleus neurons through the frequency-dependent activation of postsynaptic GABAA and GABAB receptors. J. Neurosci. 25 (2005) 6304-6315
102. Hamada I., and DeLong M.R. Excitotoxic acid lesions of the primate subthalamic nucleus result in reduced pallidal neuronal activity during active holding. J. Neurophysiol. 68 (1992) 1859-1866
103. Hartmann-von Monakow K., Akert K., and Kunzle H. Projections of the precentral motor cortex and other cortical areas of the frontal lobe to the subthalamic nucleus in the monkey. Exp. Brain Res. 33 (1978) 395-403
104. Hashimoto T., Elder C.M., Okun M.S., Patrick S.K., and Vitek J.L. Stimulation of the subthalamic nucleus changes the firing pattern of pallidal neurons. J. Neurosci. 23 (2003) 1916-1923
105. Hauser R.A., Hubble J.P., and Truong D.D. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61 (2003) 297-303
106. Herrero M.T., Levy R., Ruberg M., Javoy-Agid F., Luquin M.R., Agid Y., Hirsch E.C., and Obeso J.A. Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease. Adv. Neurol. 69 (1996) 209-216
107. Hirsch E.C., Perier C., Orieux G., Francois C., Feger J., Yelnik J., Vila M., Levy R., Tolosa E.S., Marin C., Trinidad Herrero M., Obeso J.A., and Agid Y. Metabolic effects of nigrostriatal denervation in basal ganglia. Trends Neurosci. 23 (2000) S78-S85
108. Hurlbert M.S., Gianani R.I., Hutt C., Freed C.R., and Kaddis F.G. Neural transplantation of hNT neurons for Huntington's disease. Cell Transplant 8 (1999) 143-151
109. Inase M., Buford J.A., and Anderson M.E. Changes in the control of arm position, movement, and thalamic discharge during local inactivation in the globus pallidus of the monkey. J. Neurophysiol. 75 (1996) 1087-1104
110. Isacson O., Brundin P., Gage F.H., and Bjorklund A. Neural grafting in a rat model of Huntington's disease: progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting. Neuroscience 16 (1985) 799-817
111. Isacson O., Brundin P., Kelly P.A., Gage F.H., and Bjorklund A. Functional neuronal replacement by grafted striatal neurones in the ibotenic acid-lesioned rat striatum. Nature 311 (1984) 458-460
112. Isacson O., Riche D., Hantraye P., Sofroniew M.V., and Maziere M. A primate model of Huntington's disease: cross-species implantation of striatal precursor cells to the excitotoxically lesioned baboon caudate-putamen. Exp. Brain Res. 75 (1989) 213-220
113. Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin. Investig. Drugs 14 (2005) 729-738
114. Johnston T., and Duty S. Changes in GABA(B) receptor mRNA expression in the rodent basal ganglia and thalamus following lesion of the nigrostriatal pathway. Neuroscience 120 (2003) 1027-1035
115. Katz J., Nielsen K.M., and Soghomonian J.J. Comparative effects of acute or chronic administration of levodopa to 6-hydroxydopamine-lesioned rats on the expression of glutamic acid decarboxylase in the neostriatum and GABAA receptors subunits in the substantia nigra, pars reticulata. Neuroscience 132 (2005) 833-842
116. Kawaguchi Y., Wilson C.J., Augood S.J., and Emson P.C. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci. 18 (1995) 527-535
117. Kawaguchi Y., Wilson C.J., and Emson P.C. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J. Neurosci. 10 (1990) 3421-3438
118. Keep M.F., Mastrofrancesco L., Erdman D., Murphy B., and Ashby L.S. Gamma knife subthalamotomy for Parkinson disease: the subthalamic nucleus as a new radiosurgical target. Case report. J. Neurosurg. 97 (2002) 592-599
119. Kincaid A.E., Albin R.L., Newman S.W., Penney J.B., and Young A.B. 6-Hydroxydopamine lesions of the nigrostriatal pathway alter the expression of glutamate decarboxylase messenger RNA in rat globus pallidus projection neurons. Neuroscience 51 (1992) 705-718
120. Kish S.J., Rajput A., Gilbert J., Rozdilsky B., Chang L.J., Shannak K., and Hornykiewicz O. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss. Ann. Neurol. 20 (1986) 26-31
121. Kita H., and Kitai S.T. The morphology of globus pallidus projection neurons in the rat: an intracellular staining study. Brain Res. 636 (1994) 308-319
122. Kita H., Tachibana Y., Nambu A., and Chiken S. Balance of monosynaptic excitatory and disynaptic inhibitory responses of the globus pallidus induced after stimulation of the subthalamic nucleus in the monkey. J. Neurosci. 25 (2005) 8611-8619
123. Korein J., Lieberman A., Kupersmith M., and Levidow L. Effect of L-glutamine and isoniazid on torticollis and segmental dystonia. Ann. Neurol. 10 (1981) 247-250
124. Kothare S.V., Pollack P., Kulberg A.G., and Ravin P.D. Gabapentin treatment in a child with delayed-onset hemichorea/hemiballismus. Pediatr. Neurol. 22 (2000) 68-71
125. Kouyoumdjian J.A. [Hemiballism treated with valproic acid: report of 2 cases]. Arq. Neuropsiquiatr. 42 (1984) 274-276
126. Kreil A., and Richter A. Antidystonic efficacy of gamma-aminobutyric acid uptake inhibitors in the dtsz mutant. Eur. J. Pharmacol. 521 (2005) 95-98
127. Kulisevsky J., Avila A., Berthier M.L., and Barbanoj M. Double-blind trial of flumazenil in hemiballismus. Clin. Neuropharmacol. 17 (1994) 470-472
128. Kumar R., Dagher A., Hutchison W.D., Lang A.E., and Lozano A.M. Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation. Neurology 53 (1999) 871-874
129. Kunig G., Leenders K.L., Sanchez-Pernaute R., Antonini A., Vontobel P., Verhagen A., and Gunther I. Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography. Ann. Neurol. 47 (2000) 644-648
130. Kyriagis M., Grattan-Smith P., Scheinberg A., Teo C., Nakaji N., and Waugh M. Status dystonicus and Hallervorden-Spatz disease: treatment with intrathecal baclofen and pallidotomy. J. Paediatr. Child Health 40 (2004) 322-325
131. Laprade N., and Soghomonian J.J. Gene expression of the GAD67 and GAD65 isoforms of glutamate decarboxylase is differentially altered in subpopulations of striatal neurons in adult rats lesioned with 6-OHDA as neonates. Synapse 33 (1999) 36-48
132. Lee S.T., Chu K., Park J.E., Lee K., Kang L., Kim S.U., and Kim M. Intravenous administration of human neural stem cells induces functional recovery in Huntington's disease rat model. Neurosci. Res. 52 (2005) 243-249
133. Lees A.J., Shaw K.M., and Stern G.M. Baclofen in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 41 (1978) 707-708
134. Lei W., Jiao Y., Del Mar N., and Reiner A. Evidence for differential cortical input to direct pathway versus indirect pathway striatal projection neurons in rats. J. Neurosci. 24 (2004) 8289-8299
135. Lenton R.J., Copti M., and Smith R.G. Hemiballismus treated with sodium valproate. Br. Med. J. (Clin. Res. Ed.) 283 (1981) 17-18
136. Levesque J.C., and Parent A. GABAergic interneurons in human subthalamic nucleus. Mov. Disord. 20 (2005) 574-584
137. Levy L.M., and Hallett M. Impaired brain GABA in focal dystonia. Ann. Neurol. 51 (2002) 93-101
138. Levy R., Dostrovsky J.O., Lang A.E., Sime E., Hutchison W.D., and Lozano A.M. Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. J. Neurophysiol. 86 (2001) 249-260
139. Levy R., Lang A.E., Dostrovsky J.O., Pahapill P., Romas J., Saint-Cyr J., Hutchison W.D., and Lozano A.M. Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms. Brain 124 (2001) 2105-2118
140. Lieberman D.M., Corthesy M.E., Cummins A., and Oldfield E.H. Reversal of experimental parkinsonism by using selective chemical ablation of the medial globus pallidus. J. Neurosurg. 90 (1999) 928-934
141. Loscher W., and Horstermann D. Abnormalities in amino acid neurotransmitters in discrete brain regions of genetically dystonic hamsters. J. Neurochem. 59 (1992) 689-694
142. Lozano A., Hutchison W., Kiss Z., Tasker R., Davis K., and Dostrovsky J. Methods for microelectrode-guided posteroventral pallidotomy. J. Neurosurg. 84 (1996) 194-202
143. Lundblad M., Vaudano E., and Cenci M.A. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J. Neurochem. 84 (2003) 1398-1410
144. Macia F., Escola L., Guehl D., Michelet T., Bioulac B., and Burbaud P. Neuronal activity in the monkey motor thalamus during bicuculline-induced dystonia. Eur. J. Neurosci. 15 (2002) 1353-1362
145. Madrazo I., Franco-Bourland R.E., Castrejon H., Cuevas C., and Ostrosky-Solis F. Fetal striatal homotransplantation for Huntington's disease: first two case reports. Neurol. Res. 17 (1995) 312-315
146. Magarinos-Ascone C., Pazo J.H., Macadar O., and Buno W. High-frequency stimulation of the subthalamic nucleus silences subthalamic neurons: a possible cellular mechanism in Parkinson's disease. Neuroscience 115 (2002) 1109-1117
147. Magill P.J., Bolam J.P., and Bevan M.D. Relationship of activity in the subthalamic nucleus-globus pallidus network to cortical electroencephalogram. J. Neurosci. 20 (2000) 820-833
148. Manyam B.V., Katz L., Hare T.A., Kaniefski K., and Tremblay R.D. Isoniazid-induced elevation of CSF GABA levels and effects on chorea in Huntington's disease. Ann. Neurol. 10 (1981) 35-37
149. Marco S., Perez-Navarro E., Tolosa E., Arenas E., and Alberch J. Striatopallidal neurons are selectively protected by neurturin in an excitotoxic model of Huntington's disease. J. Neurobiol. 50 (2002) 323-332
150. Marino Junior R., Benabou R., and Benabou S. Therapeutic effects of flunitrazepam in dystonias and torticollis. Preliminary communication. Arq. Neuropsiquiatr. 51 (1993) 285-286
151. Marjama-Lyons J., and Koller W. Tremor-predominant Parkinson's disease. Approaches to treatment. Drugs Aging 16 (2000) 273-278
152. Marsden C.D., and Obeso J.A. The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. Brain 117 (1994) 877-897
153. McBride J.L., Behrstock S.P., Chen E.Y., Jakel R.J., Siegel I., Svendsen C.N., and Kordower J.H. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J. Comp. Neurol. 475 (2004) 211-219
154. McIntyre C.C., Savasta M., Walter B.L., and Vitek J.L. How does deep brain stimulation work? Present understanding and future questions. J. Clin. Neurophysiol. 21 (2004) 40-50
155. Mehta A., and Chesselet M.F. Effect of GABA(A) receptor stimulation in the subthalamic nucleus on motor deficits induced by nigrostriatal lesions in the rat. Exp. Neurol. 193 (2005) 110-117
156. Meythaler J.M., Guin-Renfroe S., Grabb P., and Hadley M.N. Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience. Arch. Phys. Med. Rehabil. 80 (1999) 13-19
157. Miller W.C., and DeLong M.R. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter M.B., and Jayaraman A. (Eds). The Basal Ganglia II (1987), New York, Plenum Press 415-427
158. Mink J.W. The basal ganglia: focused selection and inhibition of competing motor programs. Prog. Neurobiol. 50 (1996) 381-425
159. Mink J.W., and Thach W.T. Basal ganglia motor control. III. Pallidal ablation: normal reaction time, muscle cocontraction, and slow movement. J. Neurophysiol. 65 (1991) 330-351
160. Mitchell I.J., Clarke C.E., Boyce S., Robertson R.G., Peggs D., Sambrook M.A., and Crossman A.R. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 32 (1989) 213-226
161. Mohler H., and Okada T. The benzodiazepine receptor in normal and pathological human brain. Br. J. Psychiatry 133 (1978) 261-268
162. Molina-Holgado E., Dewar K.M., Grondin L., van Gelder N.M., and Reader T.A. Amino acid levels and gamma-aminobutyric acidA receptors in rat neostriatum, cortex, and thalamus after neonatal 6-hydroxydopamine lesion. J. Neurochem. 60 (1993) 936-945
163. Mondrup K., Dupont E., and Braendgaard H. Progabide in the treatment of hyperkinetic extrapyramidal movement disorders. Acta Neurol. Scand. 72 (1985) 341-343
164. Morselli, P.L., Fournier, V., Bossi, L. and Musch, B. (1985) Clinical activity of GABA agonists in neuroleptic- and L-dopa-induced dyskinesia. Psychopharmacology Suppl., 2: 128-136.
165. Nakanishi H., Kita H., and Kitai S.T. Electrical membrane properties of rat subthalamic neurons in an in vitro slice preparation. Brain Res. 437 (1987) 35-44
166. Nakao N., Ogura M., Nakai K., and Itakura T. Embryonic striatal grafts restore neuronal activity of the globus pallidus in a rodent model of Huntington's disease. Neuroscience 88 (1999) 469-477
167. Nambu A., and Llinas R. Electrophysiology of globus pallidus neurons in vitro. J. Neurophysiol. 72 (1994) 1127-1139
168. Nambu A., Tokuno H., Hamada I., Kita H., Imanishi M., Akazawa T., Ikeuchi Y., and Hasegawa N. Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey. J. Neurophysiol. 84 (2000) 289-300
169. Nambu A., Tokuno H., and Takada M. Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci. Res. 43 (2002) 111-117
170. Nicholson L.F., Faull R.L., Waldvogel H.J., and Dragunow M. GABA and GABAA receptor changes in the substantia nigra of the rat following quinolinic acid lesions in the striatum closely resemble Huntington's disease. Neuroscience 66 (1995) 507-521
171. Nobrega J.N., Richter A., Burnham W.M., and Loscher W. Alterations in the brain GABAA/benzodiazepine receptor-chloride ionophore complex in a genetic model of paroxysmal dystonia: a quantitative autoradiographic analysis. Neuroscience 64 (1995) 229-239
172. Nutt J., Williams A., Plotkin C., Eng N., Ziegler M., and Calne D.B. Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological, and biochemical observations. Can. J. Neurol. Sci. 6 (1979) 337-343
173. Obeso J.A., Olanow C.W., and Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23 (2000) S2-S7
174. Ochi M., Shiozaki S., and Kase H. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease. Neuroscience 127 (2004) 223-231
175. Ondo W.G., and Hunter C. Flumazenil, a GABA antagonist, may improve features of Parkinson's disease. Mov. Disord. 18 (2003) 683-685
176. Pan H.S., Penney J.B., and Young A.B. Gamma-aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle. J. Neurochem. 45 (1985) 1396-1404
177. Papa S.M., Desimone R., Fiorani M., and Oldfield E.H. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann. Neurol. 46 (1999) 732-738
178. Parent A., Sato F., Wu Y., Gauthier J., Levesque M., and Parent M. Organization of the basal ganglia: the importance of axonal collateralization. Trends Neurosci. 23 (2000) S20-S27
179. Pearlman S.H., Levivier M., Collier T.J., Sladek Jr. J.R., and Gash D.M. Striatal implants protect the host striatum against quinolinic acid toxicity. Exp. Brain Res. 84 (1991) 303-310
180. Pedneault S., and Soghomonian J.J. Glutamate decarboxylase (GAD65) mRNA levels in the striatum and pallidum of MPTP-treated monkeys. Brain Res. Mol. Brain Res. 25 (1994) 351-354
181. Penn R.D., Gianino J.M., and York M.M. Intrathecal baclofen for motor disorders. Mov. Disord. 10 (1995) 675-677
182. Penn R.D., Kroin J.S., Reinkensmeyer A., and Corcos D.M. Injection of GABA-agonist into globus pallidus in patient with Parkinson's disease. Lancet 351 (1998) 340-341
183. Perez-Navarro E., Akerud P., Marco S., Canals J.M., Tolosa E., Arenas E., and Alberch J. Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease. Neuroscience 98 (2000) 89-96
184. Perez-Navarro E., Canudas A.M., Akerund P., Alberch J., and Arenas E. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J. Neurochem. 75 (2000) 2190-2199
185. Perry T.L., Javoy-Agid F., Agid Y., and Fibiger H.C. Striatal GABAergic neuronal activity is not reduced in Parkinson's disease. J. Neurochem. 40 (1983) 1120-1123
186. Perry T.L., Wright J.M., Hansen S., and MacLeod P.M. Isoniazid therapy of Huntington disease. Neurology 29 (1979) 370-375
187. Philpott L.M., Kopyov O.V., Lee A.J., Jacques S., Duma C.M., Caine S., Yang M., and Eagle K.S. Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations. Cell Transplant 6 (1997) 203-212
188. Pina M.A., and Modrego P.J. Dystonia induced by gabapentin. Ann. Pharmacother. 39 (2005) 380-382
189. Pinal C.S., and Tobin A.J. Uniqueness and redundancy in GABA production. Perspect. Dev. Neurobiol. 5 (1998) 109-118
190. Pinna A., Wardas J., Simola N., and Morelli M. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life Sciences 77 (2005) 3259-3267
191. Playford E.D., Passingham R.E., Marsden C.D., and Brooks D.J. Increased activation of frontal areas during arm movement in idiopathic torsion dystonia. Mov. Disord. 13 (1998) 309-318
192. Plenz D., and Kitai S. A basal ganglia pacemaker formed by the subthalamic nucleus and external globus pallidus. Nature 400 (1999) 677-682
193. Postuma R.B., and Lang A.E. Hemiballism: revisiting a classic disorder. Lancet Neurol. 2 (2003) 661-668
194. Pratt G.D., Richter A., Mohler H., and Loscher W. Regionally selective and age-dependent alterations in benzodiazepine receptor binding in the genetically dystonic hamster. J. Neurochem. 64 (1995) 2153-2158
195. Przuntek H. Non-dopaminergic therapy in Parkinson's disease. J. Neurol. 247 Suppl. 2 (2000) II19-II24
196. Pundt L.L., Kondoh T., Conrad J.A., and Low W.C. Transplantation of human striatal tissue into a rodent model of Huntington's disease: phenotypic expression of transplanted neurons and host-to-graft innervation. Brain Res. Bull. 39 (1996) 23-32
197. Rabey J.M., Orlov E., and Spiegelman R. Levodopa-induced dyskinesias are the main feature improved by contralateral pallidotomy in Parkinson's disease. Neurology 45 (1995) A377
198. Reddy P.H., Williams M., and Tagle D.A. Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci. 22 (1999) 248-255
199. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., and Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. USA 85 (1988) 5733-5737
200. Reisine T.D., Overstreet D., Gale K., Rossor M., Iversen L., and Yamamura H.I. Benzodiazepine receptors: the effect of GABA on their characteristics in human brain and their alteration in Huntington's disease. Brain Res. 199 (1980) 79-88
201. Reynolds G.P., Pearson S.J., and Heathfield K.W. Dementia in Huntington's disease is associated with neurochemical deficits in the caudate nucleus, not the cerebral cortex. Neurosci. Lett. 113 (1990) 95-100
202. Robertson R.G., Clarke C.A., Boyce S., Sambrook M.A., and Crossman A.R. The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3 H]flunitrazepam autoradiography. Brain Res. 531 (1990) 95-104
203. Robertson R.G., Graham W.C., Sambrook M.A., and Crossman A.R. Further investigations into the pathophysiology of MPTP-induced parkinsonism in the primate: an intracerebral microdialysis study of gamma-aminobutyric acid in the lateral segment of the globus pallidus. Brain Res. 563 (1991) 278-280
204. Rosse R.B., Allen A., and Lux W.E. Baclofen treatment in a patient with tardive dystonia. J. Clin. Psychiatry 47 (1986) 474-475
205. Rupniak N.M., Jenner P., and Marsden C.D. Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl.) 88 (1986) 403-419
206. Salin P., Manrique C., Forni C., and Kerkerian-Le Goff L. High-frequency stimulation of the subthalamic nucleus selectively reverses dopamine denervation-induced cellular defects in the output structures of the basal ganglia in the rat. J. Neurosci. 22 (2002) 5137-5148
207. Sanberg P.R., Henault M.A., and Deckel A.W. Locomotor hyperactivity: effects of multiple striatal transplants in an animal model of Huntington's disease. Pharmacol. Biochem. Behav. 25 (1986) 297-300
208. Sandyk R. Beneficial effect of sodium valproate and baclofen in spasmodic torticollis. A case report. S. Afr. Med. J. 65 (1984) 62-63
209. Schneider J.S., and Wade T.V. Experimental parkinsonism is associated with increased pallidal GAD gene expression and is reversed by site-directed antisense gene therapy. Mov. Disord. 18 (2003) 32-40
210. Schroeder J.A., and Schneider J.S. GABA-opioid interactions in the globus pallidus: [D-Ala2]-Met-enkephalinamide attenuates potassium-evoked GABA release after nigrostriatal lesion. J. Neurochem. 82 (2002) 666-673
211. Schultz W. The phasic reward signal of primate dopamine neurons. Adv. Pharmacol. 42 (1998) 686-690
212. Schumacher J.M., Hantraye P., Brownell A.L., Riche D., Madras B.K., Davenport P.D., Maziere M., Elmaleh D.R., Brownell G.L., and Isacson O. A primate model of Huntington's disease: functional neural transplantation and CT-guided stereotactic procedures. Cell Transplant 1 (1992) 313-322
213. Schwartzman R.J., and Alexander G.M. Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson's disease. Brain Res. 358 (1985) 137-143
214. Scigliano G., Giovannini P., Girotti F., Grassi M.P., Caraceni T., and Schechter P.J. Gamma-vinyl GABA treatment of Huntington's disease. Neurology 34 (1984) 94-96
215. Scoditti U., Rustichelli P., and Calzetti S. Spontaneous hemiballism and disappearance of parkinsonism following contralateral lenticular lacunar infarct. Ital. J. Neurol. Sci. 10 (1989) 575-577
216. Segawa M. Hereditary progressive dystonia with marked diurnal fluctuation. Brain Dev. 22 Suppl. 1 (2000) S65-S80
217. Segawa M., Hosaka A., Miyagawa F., Nomura Y., and Imai H. Hereditary progressive dystonia with marked diurnal fluctuation. In: Eldridge R., and Fahn S. (Eds). Adv. Neurol. (1976), Raven Press, New York 215-233
218. Sellal F., Lisovoski F., Hirsch E., Mutschler V., Collard M., and Marescaux C. Contralateral disappearance of parkinsonian signs after subthalamic hematoma. Neurology 42 (1992) 255
219. Semyanov A., Walker M.C., Kullmann D.M., and Silver R.A. Tonically active GABAA receptors: modulating gain and maintaining the tone. Trends Neurosci. 27 (2004) 262-269
220. Shink E., Bevan M.D., Bolam J.P., and Smith Y. The subthalamic nucleus and the external pallidum: two tightly interconnected structures that control the output of the basal ganglia in the monkey. Neuroscience 73 (1996) 335-357
221. Shoulson I., Goldblatt D., Charlton M., and Joynt R.J. Huntington's disease: treatment with muscimol, a GABA-mimetic drug. Ann. Neurol. 4 (1978) 279-284
222. Shoulson I., Kartzinel R., and Chase T.N. Huntington's disease: treatment with dipropylacetic acid and gamma-aminobutyric acid. Neurology 26 (1976) 61-63
223. Sieradzan K.A., Fox S.H., Hill M., Dick J.P., Crossman A.R., and Brotchie J.M. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57 (2001) 2108-2111
224. Silberstein P., Kuhn A.A., Kupsch A., Trottenberg T., Krauss J.K., Wohrle J.C., Mazzone P., Insola A., Di Lazzaro V., Oliviero A., Aziz T., and Brown P. Patterning of globus pallidus local field potentials differs between Parkinson's disease and dystonia. Brain 126 (2003) 2597-2608
225. Silbert P.L., and Stewart-Wynne E.G. Increased dystonia after intrathecal baclofen. Neurology 42 (1992) 1639-1640
226. Smith Y., Bevan M.D., Shink E., and Bolam J.P. Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience 86 (1998) 353-387
227. Smith Y., Raju D.V., Pare J.F., and Sidibe M. The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci. 27 (2004) 520-527
228. Soares J., Kliem M.A., Betarbet R., Greenamyre J.T., Yamamoto B., and Wichmann T. Role of external pallidal segment in primate parkinsonism: comparison of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism and lesions of the external pallidal segment. J. Neurosci. 24 (2004) 6417-6426
229. Soghomonian J.J., and Laprade N. Glutamate decarboxylase (GAD67 and GAD65) gene expression is increased in a subpopulation of neurons in the putamen of parkinsonian monkeys. Synapse 27 (1997) 122-132
230. Soghomonian J.J., and Martin D.L. Two isoforms of glutamate decarboxylase: why?. Trends Pharmacol. Sci. 19 (1998) 500-505
231. Soghomonian J.J., Pedneault S., Audet G., and Parent A. Increased glutamate decarboxylase mRNA levels in the striatum and pallidum of MPTP-treated primates. J. Neurosci. 14 (1994) 6256-6265
232. Soghomonian J.J., Pedneault S., Blanchet P.J., Goulet M., Di Paolo T., and Bedard P.J. L-DOPA regulates glutamate decarboxylases mRNA levels in MPTP-treated monkeys. Brain Res. Mol. Brain Res. 39 (1996) 237-240
233. Spokes E.G. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain 103 (1980) 179-210
234. Stanford I.M. Independent neuronal oscillators of the rat globus pallidus. J. Neurophysiol. 89 (2003) 1713-1717
235. Starr P.A., Rau G.M., Davis V., Marks Jr. W.J., Ostrem J.L., Simmons D., Lindsey N., and Turner R.S. Spontaneous pallidal neuronal activity in human dystonia: comparison with Parkinson's disease and normal macaque. J. Neurophysiol. 93 (2005) 3165-3176
236. Stasi K., Mitsacos A., Giompres P., Kouvelas E.D., and Triarhou L.C. Partial restoration of striatal GABAA receptor balance by functional mesencephalic dopaminergic grafts in mice with hereditary parkinsonism. Exp. Neurol. 157 (1999) 259-267
237. Storey E., and Beal M.F. Neurochemical substrates of rigidity and chorea in Huntington's disease. Brain 116 (1993) 1201-1222
238. Su P.C., Tseng H.M., Liu H.M., Yen R.F., and Liou H.H. Treatment of advanced Parkinson's disease by subthalamotomy: one-year results. Mov. Disord. 18 (2003) 531-538
239. Suarez J.I., Metman L.V., Reich S.G., Dougherty P.M., Hallett M., and Lenz F.A. Pallidotomy for hemiballismus: efficacy and characteristics of neuronal activity. Ann. Neurol. 42 (1997) 807-811
240. Surmeier D.J., Eberwine J., Wilson C.J., Cao Y., Stefani A., and Kitai S.T. Dopamine receptor subtypes colocalize in rat striatonigral neurons. Proc. Natl. Acad. Sci. USA 89 (1992) 10178-10182
241. Symington G.R., Leonard D.P., Shannon P.J., and Vajda F.J. Sodium valproate in Huntington's disease. Am. J. Psychiatry 135 (1978) 352-354
242. Tasker R.R., Lang A.E., and Lozano A.M. Pallidal and thalamic surgery for Parkinson's disease. Exp. Neurol. 144 (1997) 35-40
243. Tell G., Bohlen P., Schechter P.J., Koch-Weser J., Agid Y., Bonnet A.M., Coquillat G., Chazot G., and Fischer C. Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration. Neurology 31 (1981) 207-211
244. Tenn C.C., and Niles L.P. Mechanisms underlying the antidopaminergic effect of clonazepam and melatonin in striatum. Neuropharmacology 36 (1997) 1659-1663
245. Tepper J.M., Koos T., and Wilson C.J. GABAergic microcircuits in the neostriatum. Trends Neurosci. 27 (2004) 662-669
246. Terman D., Rubin J.E., Yew A.C., and Wilson C.J. Activity patterns in a model for the subthalamopallidal network of the basal ganglia. J. Neurosci. 22 (2002) 2963-6976
247. Thaker G.K., Nguyen J.A., Strauss M.E., Jacobson R., Kaup B.A., and Tamminga C.A. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am. J. Psychiatry 147 (1990) 445-451
248. Thompson-Vest N.M., Waldvogel H.J., Rees M.I., and Faull R.L. GABA(A) receptor subunit and gephyrin protein changes differ in the globus pallidus in Huntington's diseased brain. Brain Res. 994 (2003) 265-270
249. van der Stelt M., Fox S.H., Hill M., Crossman A.R., Petrosino S., Di Marzo V., and Brotchie J.M. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J. 19 (2005) 1140-1142
250. Van Ness P.C., Watkins A.E., Bergman M.O., Tourtellotte W.W., and Olsen R.W. gamma-Aminobutyric acid receptors in normal human brain and Huntington disease. Neurology 32 (1982) 63-68
251. Vidakovic A., Dragasevic N., and Kostic V.S. Hemiballism: report of 25 cases. J. Neurol. Neurosurg. Psychiatry 57 (1994) 945-949
252. Vitek J.L. Pathophysiology of dystonia: a neuronal model. Mov. Disord. 17 Suppl. 3 (2002) S49-S62
253. Vitek J.L., Chockkan V., Zhang J.Y., Kaneoke Y., Evatt M., DeLong M.R., Triche S., Mewes K., Hashimoto T., and Bakay R.A. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann. Neurol. 46 (1999) 22-35
254. e) segments of the globus pallidus (GP) of parkinsonian patients is similar to that in the MPTP-treated primate model of parkinsonism. Soc. Neurosci. Abstr. 19 (1993) 1584
255. Walker F.O., Young A.B., Penney J.B., Dovorini-Zis K., and Shoulson I. Benzodiazepine and GABA receptors in early Huntington's disease. Neurology 34 (1984) 1237-1240
256. Wenger K.K., Musch K.L., and Mink J.W. Impaired reaching and grasping after focal inactivation of globus pallidus pars interna in the monkey. J. Neurophysiol. 82 (1999) 2049-2060
257. Whittier J.R., and Mettler F.A. Studies of the subthalamus of the rhesus monkey. II. Hyperkinesia and other physiologic effects of subthalamic lesions with special references to the subthalamic nucleus of Luys. J. Comp. Neurol. 90 (1949) 319-372
258. Wichmann T., Bergman H., and DeLong M.R. The primate subthalamic nucleus. I. Functional properties in intact animals. J. Neurophysiol. 72 (1994) 494-506
259. Wichmann T., Bergman H., and DeLong M.R. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J. Neurophysiol. 72 (1994) 521-530
260. Wichmann T., Bergman H., Starr P.A., Subramanian T., Watts R.L., and DeLong M.R. Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates. Exp. Brain Res. 125 (1999) 397-409
261. Wichmann T., and DeLong M.R. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv. Neurol. 91 (2003) 9-18
262. Wichmann T., Gatev P.G., and Kliem M.A. Neuronal discharge in the basal ganglia is correlated with EEG in normal and parkinsonina primates. Mov. Disord. (Abstract Volume) 17 Suppl. 5 (2002) S155
263. Wichmann T., Kliem M.A., and DeLong M.R. Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates. Exp. Neurol. 167 (2001) 410-424
264. Wilson C.J., and Groves P.M. Fine structure and synaptic connections of the common spiny neuron of the rat neostriatum: a study employing intracellular inject of horseradish peroxidase. J. Comp. Neurol. 194 (1980) 599-615
265. Windels F., Bruet N., Poupard A., Urbain N., Chouvet G., Feuerstein C., and Savasta M. Effects of high frequency stimulation of subthalamic nucleus on extracellular glutamate and GABA in substantia nigra and globus pallidus in the normal rat. Eur. J. Neurosci. 12 (2000) 4141-4146
266. Windels F., Carcenac C., Poupard A., and Savasta M. Pallidal origin of GABA release within the substantia nigra pars reticulata during high-frequency stimulation of the subthalamic nucleus. J. Neurosci. 25 (2005) 5079-5086
267. Winkler C., Bentlage C., Nikkhah G., Samii M., and Bjorklund A. Intranigral transplants of GABA-rich striatal tissue induce behavioral recovery in the rat Parkinson model and promote the effects obtained by intrastriatal dopaminergic transplants. Exp. Neurol. 155 (1999) 165-186
268. Wu Y., Richard S., and Parent A. The organization of the striatal output system: a single-cell juxtacellular labeling study in the rat. Neurosci. Res. 38 (2000) 49-62
269. Yoshida M., Nagatsuka Y., Muramatsu S., and Niijima K. Differential roles of the caudate nucleus and putamen in motor behavior of the cat as investigated by local injection of GABA antagonists. Neurosci. Res. 10 (1991) 34-51
270. Yu T.S., Wang S.D., Liu J.C., and Yin H.S. Changes in the gene expression of GABA(A) receptor alpha1 and alpha2 subunits and metabotropic glutamate receptor 5 in the basal ganglia of the rats with unilateral 6-hydroxydopamine lesion and embryonic mesencephalic grafts. Exp. Neurol. 168 (2001) 231-241